Trial Profile
A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2013
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary) ; Beclometasone
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
- 13 Sep 2006 New trial record.